相关实验视频
Updated: Jul 28, 2026

07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
在高胆固醇血症患者的冠状动脉微循环中纠正内皮功能障碍的L-阿尔金宁
H Drexler1, A M Zeiher, K Meinzer
1Medizinische Klinik III, Universität Freiburg, Germany.
Lancet (London, England)
|December 21, 1991
概括
高胆固醇会损害血管功能,减少血液流动. 在高胆固醇血症患者中,补充L-氨酸成功地恢复了正常的血液流动,这表明内皮功能障碍的潜在治疗方法.
科学领域:
- 心血管医学 心血管医学
- 内皮功能研究研究 内皮功能研究
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 高胆固醇血症与内皮功能受损有关.
- 内皮功能障碍可能源于氧化 (NO) 的生物可用性降低,可能是由于L-氨酸缺乏症.
- 冠状动脉循环对高胆固醇血症的反应需要进一步调查.
研究的目的:
- 调查L-阿尔金宁是否可以逆转高胆固醇血症患者内皮功能障碍.
- 评估L-氨酸对冠状动脉血流和心上动脉功能的影响.
主要方法:
- 该研究包括8名高胆固醇血症患者和7名对照.
- 测量了心上动脉直径和冠状动脉血流速度.
- 通过冠内输液给药的乙胆 (依赖内皮质的药物) 和L-阿尔金因.
主要成果:
- 与对照组相比,高胆固醇血症患者表现出减弱的乙胆诱导的冠状动脉血流增加.
- 在高胆固醇血症患者中,L-氨酸输液恢复了乙胆诱导的冠状动脉血流增加.
- 在对照人群中,L-氨酸没有影响冠状动脉血流.
结论:
- 高胆固醇血症会损害冠状动脉微循环中的内皮依赖扩张.
- 短期的L-氨酸的使用可以扭转这种损伤.
- 氨酸显示出作为治疗高胆固醇血症诱导的内皮功能障碍的治疗剂的潜力.
相关概念视频
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

